Adipose-Derived Regenerative Cells for the Treatment of Patients with Non-revascularisable Ischaemic Cardiomyopathy - The PRECISE Trial

Login or register to view PDF.
Disclosure
The authors are employees of Cytori Therapeutics.
Correspondence
Priya Sridhar, Cytori Therapeutics, 3020 Callan Road, San Diego, CA 92121, US. E: psridhar@cytori.com
Support
The publication of this article was supported by Cytori Therapeutics.
Received date
02 July 2012
Accepted date
07 July 2012
DOI
https://doi.org/10.15420/icr.2012.7.2.77

Abstract

Adipose-derived regenerative cells (ADRCs) continue to be evaluated for use in the treatment of patients with chronic heart failure, particularly in those refractory to, or not suitable for, currently available options. This population of cells has demonstrated the ability to facilitate wound repair through the restoration of blood flow in ischaemic conditions, reduction in inflammation and apoptosis, and regeneration of damaged tissue through stem cell differentiation into multiple cell lineages, including cardiac muscle. This approach is particularly useful in the repair or restoration of function to ischaemic tissues in patients where the body's natural repair mechanisms have failed or been exhausted, such as patients with non-revascularisable, refractory heart failure. The use of ADRCs for these patients has numerous advantages. Primarily, the cells are accessed from a patient's own tissue, minimising the risk of disease transmission or rejection. Further, the heterogeneity of the cells generates an orchestrated response that targets all phases of the wound healing process. Finally, the cells are readily accessible in real-time without the need for cell expansion, making it a virtually off-the-shelf therapy option. The Celution® System is a safe, GMP-compliant technology designed to automate the preparation of ADRCs at the patient's bedside. It has been clinically validated for safety and feasibility in two completed cardiac trials; one for acute myocardial infarction and the other for chronic myocardial ischaemia. It is being further evaluated in two ongoing clinical trials for the same indications. In this article, a summary of 18-month follow-up data using the Celution technology for the treatment of patients with non-revascularisable, symptomatic, ischaemic cardiomyopathy will be presented. While additional studies are planned to confirm the efficacy of these cells in the cardiac setting, early clinical data shows promising trends towards the improvement of cardiac function and mortality rate using a technology that can potentially significantly reduce treatment costs compared to the current standard-of-care.

To view the full article, please click on the PDF icon.

References
  1. Zuk PA, Zhu M, Mizuno H, et al., Multilineage cells from human adipose tissue: implications for cell-based therapies, Tissue Eng, 2001;7(2):211–28.
    Crossref | PubMed
  2. Choi YS, Dusting GJ, Stubbs S, et al., Differentiation of human adipose-derived stem cells into beating cardiomyocytes, J Cell Mol Med, 2010;14:878–89.
    Crossref | PubMed
  3. Rehman J, Traktuev D, Li J, et al., Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells, Circulation, 2004;109:1292–8.
    Crossref | PubMed
  4. Moseley TA, Zhu M, Hedrick MH, et al., Adipose-derived stem and progenitor cells as fillers in plastic surgery, Plastic and Reconstructive Surgery, 2006;118(3 Suppl.):121S–9S.
    Crossref | PubMed
  5. Pfeffer MA, I Braunwald E, Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications, Circulation, 1990;81(4):1161–72.
    Crossref | PubMed
  6. Lin K, Matsubara Y, Masuda Y, et al., Characterization of adipose tissue-derived cells isolated with the Celution system, Cytotherapy, 2008;10(4):417–26.
    Crossref | PubMed